|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Patrick Le Gal explains how his company deployed a quality by design approach to manage all the unavoidable competing requirements and to propose a solution that balances performance, robustness, and usability.
|
|
|
Hillel Cohen, PhD, outlines the evolution of biosimilar approvals and describes the process of analytical and clinical testing followed in the development of a biosimilar, with use of data from the scientific literature.
|
|
|
Marianna Tcherpakov, PhD, discusses underexploited strategies, traditional approaches that can be optimized, novel techniques beginning to emerge and pay dividends, and results propelling this field toward better clinical outcomes.
|
|
|
Jim Huang, PhD, discusses the issues associated with amorphous formulations, including solid state stability, chemical stability, reproducibility of API manufacturing, impurity of API, stability in aqueous solution, in vitro in vivo performance, and process and scale-up.
|
|
|
|
|
|
|
|
|

As one of the world’s most renowned companies for contract development and manufacturing, Lonza Pharma & Biotech is recognized for our reliable, high-quality services, our global capacity, our innovative technology platforms, and our extensive experience. From 2013 to 2016, our contributions supported 36% of launches with small-molecule breakthrough designation. In 2016 alone, we provided manufacturing services for more than 50 commercial molecules and conducted more than 250 development programs. We have helped launch pioneering autologous cell therapies. Click here for more.

EG-GILERO is truly different from other outsource partners. Design & Development is in our DNA. Our experienced engineering team provides a full suite of design and development services for your medical device and drug delivery device product development projects. Beginning with the end user in mind, EG-GILERO conducts clinical site user research, novel concept development, smart rapid prototyping, detailed engineering, and intellectual property (IP) management. By adhering to strict design controls and our ISO 13485 certified quality management system (QMS), EG-GILERO integrates human factors engineering (HE75) and design for manufacturability (DFM) throughout the entire development process. Click here for more.
|
|
|
|
|
|
 |
|
As the pipeline of biologic drugs intended to treat complex disease expands, the typical timeline for drug development seems to be shortening more frequently and with more intensity……..
|
|
 |
|
AptarGroup, Inc. recently announced it has acquired two leading pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical LLC, for a combined enterprise value of approximately $50 million.
|
|
 |
|
Enable Injections, Inc. recently announced it has entered into a multi-product development agreement with Sanofi S.A.
|
|
 |
|
PCI Pharma Services, a leading biopharmaceutical outsourcing services provider, recently announced the growth of its West Coast Clinical operations with expansion into its third facility in San Diego.
|
|
 |
|
Verseon recently presented a new class of oral candidate drugs, which could not only revolutionize the treatment of diabetic macular edema (DME), but could also be effective in preventing this increasingly common condition.
|
|
 |
|
Cambrex Corporation recently announced it has completed a new facility at its site in Karlskoga, Sweden, which incorporates new laboratories for process and analytical development.
|
|
|
|
|
Upcoming eNewsletter Features:
June 19 – Parenteral Contract Manufacturing
June 26 – Controlled Release
|
|
|
|
|
|
|
|